What is Zacks Small Cap’s Estimate for CVKD FY2024 Earnings?

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Investment analysts at Zacks Small Cap raised their FY2024 earnings per share (EPS) estimates for shares of Cadrenal Therapeutics in a research note issued to investors on Wednesday, November 20th. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings per share of ($7.18) for the year, up from their prior estimate of ($8.17). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Zacks Small Cap also issued estimates for Cadrenal Therapeutics’ Q4 2024 earnings at ($1.41) EPS.

Separately, HC Wainwright upped their price objective on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, November 11th.

Cadrenal Therapeutics Trading Up 7.0 %

Shares of CVKD stock opened at $14.99 on Friday. Cadrenal Therapeutics has a 1-year low of $5.40 and a 1-year high of $32.55. The stock has a market capitalization of $24.88 million, a price-to-earnings ratio of -2.24 and a beta of 1.52. The stock’s 50-day moving average is $14.40.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.